Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Pembrolizumab in Advanced Anorectal Squamous Cell Carcinoma
NCT06669572Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Jul 2025
- Primary completion
- Mar 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in Anorectal Squamous Cell Carcinoma, sponsored by University of Chicago. Primary endpoint: Objective Response Rate at 2 years. Started Jul 2025; status: recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
Anorectal Squamous Cell Carcinoma
Beyond the preview
Go deeper on NCT06669572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669572.